Utilizing shared compound libraries for novel LDC targets
First LDC-lead structure successfully progressed by Bayer Pharma AG into clinical study phase
The Max Planck Institute of Biochemistry (MPIB), the Lead Discovery Center GmbH (LDC) and Qurient Co., Ltd have entered into a license agreement providing Qurient with world-wide
Successful Transfer into Pre-Clinical Drug Development at Bayer Pharma AG
Page 1 of 1